REMARKS

Prior to examination of the above-identified application, entry of the foregoing, and consideration of the above amendments are respectfully requested.

Claims 3 and 4 have been amended to more clearly recite a pharmaceutical composition. These amendments do not narrow the scope of the claims in any regard. Claims 6 and 7 have been amended to be independent claims. New claims 11-17 have been added to recite methods of treatment. Support for these claims may be found at the very least in the original claims 1-8. It is respectfully submitted that no new matter has been added by the above amendments.

In the event that there are any questions relating to this Preliminary Amendment, or to the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney at 508-339-3684 concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____
Donna M. Meuth
Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: October 1, 2001

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7

3. (Amended) A [preventive or therapeutic] pharmaceutical composition [for diseases accompanied by abnormal vascular function] comprising a chymase inhibitor in [, wherein the chymase inhibitor is blended at] an amount [that suppresses] effective for suppressing lipid deposition in the blood vessel and a pharmaceutically acceptable carrier therefor.

4. (Amended) The [preventive or therapeutic] pharmaceutical composition according to claim 3, wherein the disease accompanied by abnormal vascular function in which lipid deposition in the blood vessel is involved is selected from the group consisting of arteriosclerosis, cardiac acute coronary syndrome, restenosis after percutaneous transluminal coronary angioplasty, obstructive arteriosclerosis, obstructive thrombotic vasculitis, atherosclerosis, cerebral infarction, intermittent claudication, lower limb gangrene, renal vascular hypertension, renal arterial aneurysm and renal infarction.

6. (Twice Amended) [The] A preventive or therapeutic agent for diseases accompanied by abnormal vascular function in which lipid depositino in the blood vessel is involved [according to claim 1, wherein said chymase inhibitor is] comprising a quinazoline derivative represented by the formula (1):

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7



(1)

wherein, the ring A represents an aryl ring,

R^1 represents a hydroxy group, an amino group, or a lower alkylamino group having 1 to 4 carbons that may be substituted with a carboxylic group, a lower aralkylamino group having 7 to 10 carbons that may be substituted with a carboxylic group, an amino group acylated with a lower fatty acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group acylated with an aromatic carboxylic acid that may be substituted with a carboxylic group, an amino group acylated with a

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7

heteroaromatic carboxylic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a lower alkanesulfonic acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group sulfonylated with an aromatic sulfonic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a heteroaromatic sulfonic acid that may be substituted with a carboxylic group, a lower alkyl group having 1 to 4 carbons substituted with a carboxylic group, or a lower alkylene group having 2 to 4 carbons substituted with a carboxylic group;

R^2 and R^3, which may be the same or different, represent a hydrogen, a lower alkyl group having 1 to 4 carbons that may be substituted, a halogen atom, a hydroxy group, a lower alkoxy group having 1 to 4 carbons, an amino group, a lower alkylamino group having 1 to 4 carbons that may be substituted, a lower aralkylamino group having 7 to 10 carbons that may be substituted, an amino group acylated with a lower fatty acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group acylated with an aromatic carboxylic acid that may be substituted with a carboxylic group, an amino group acylated with a heteroaromatic carboxylic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a lower alkanesulfonic acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group sulfonylated with an aromatic sulfonic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a heteroaromatic sulfonic acid that may be substituted with a carboxylic group, or a carboxylic group; or

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7

when the ring A is a benzene ring, R^1 and R^2, together with the benzene ring to be substituted, may form a fused heterocyclic ring that may be substituted with a carboxylic acid, and a carbon atom in said fused heterocyclic ring may form a carbonyl group wherein R^3 is as defined above; and

X represents a hydrogen atom, a lower alkyl group having 1 to 4 carbons, a lower alkoxy group having 1 to 4 carbons, a halogen atom, a hydroxy group, an amino group, or a nitro group;

or a pharmaceutically acceptable salt thereof.

7. (Twice Amended) [The] A pharmaceutical composition [according to claim 3, wherein said chymase inhibitor is] comprising a quinazoline derivative represented by the formula (1):

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7



(1)

wherein, the ring A represents an aryl ring,

R^1 represents a hydroxy group, an amino group, or a lower alkylamino group having 1 to 4 carbons that may be substituted with a carboxylic group, a lower aralkylamino group having 7 to 10 carbons that may be substituted with a carboxylic group, an amino group acylated with a lower fatty acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group acylated with an aromatic carboxylic acid that may be substituted with a carboxylic group, an amino group acylated with a heteroaromatic carboxylic acid that may be substituted with a carboxylic group, an amino

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7

group sulfonylated with a lower alkanesulfonic acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group sulfonylated with an aromatic sulfonic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a heteroaromatic sulfonic acid that may be substituted with a carboxylic group, a lower alkyl group having 1 to 4 carbons substituted with a carboxylic group, or a lower alkylene group having 2 to 4 carbons substituted with a carboxylic group;

R^2 and R^3, which may be the same or different, represent a hydrogen, a lower alkyl group having 1 to 4 carbons that may be substituted, a halogen atom, a hydroxy group, a lower alkoxy group having 1 to 4 carbons, an amino group, a lower alkylamino group having 1 to 4 carbons that may be substituted, a lower aralkylamino group having 7 to 10 carbons that may be substituted, an amino group acylated with a lower fatty acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group acylated with an aromatic carboxylic acid that may be substituted with a carboxylic group, an amino group acylated with a heteroaromatic carboxylic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a lower alkanesulfonic acid having 1 to 4 carbons that may be substituted with a carboxylic group, an amino group sulfonylated with an aromatic sulfonic acid that may be substituted with a carboxylic group, an amino group sulfonylated with a heteroaromatic sulfonic acid that may be substituted with a carboxylic group, or a carboxylic group; or

Attachment to Second Preliminary Amendment dated September 28, 2001

Marked-up Claims 3, 4 and 6-7

when the ring A is a benzene ring, R^1 and R^2, together with the benzene ring to be substituted, may form a fused heterocyclic ring that may be substituted with a carboxylic acid, and a carbon atom in said fused heterocyclic ring may form a carbonyl group wherein R^3 is as defined above; and

X represents a hydrogen atom, a lower alkyl group having 1-4 carbons, a lower alkoxy group having 1 to 4 carbons, a halogen atom, a hydroxy group, an amino group, or a nitro group;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.